Results 121 to 130 of about 26,826 (219)

Role of Otolaryngology in Monitoring the Progression of Myotonic Dystrophy: A Case Report. [PDF]

Cureus
Pudi V, Shah A.
europepmc   +1 more source

Fading Muscle and a Flaccid Bladder: Atonic Bladder in a Case of Myotonic Dystrophy-A Case Report. [PDF]

Ann Neurosci
Ravichandran PY, R K, Madhavan K.
europepmc   +1 more source

Toward Trial Readiness in Congenital Myotonic Dystrophy: A Longitudinal Cohort Study of Predictors of Motor Function in Childhood. [PDF]

Neurol Genet
Kiefer M, Hartman JM, Berggren KN, Butler A, Jones AS, McIntyre M, Hung M, Carrell S, Hale MA, Campbell C, Sansone VA, Johnson NE.   +11 more
europepmc   +1 more source

Commitment to Myogenic Differentiation Significantly Aggravates the RNA Phenotype in Myotonic Dystrophy Type 1. [PDF]

Neuropathol Appl Neurobiol
Ripken L, van den Broek WJAA, van Cruchten RTP, Smits JGA, Riepe TV, 't Hoen PAC, Wansink DG.   +6 more
europepmc   +1 more source

Cardiac conduction abnormalities in myotonic dystrophy type I: The ongoing value of the ECG. [PDF]

Int J Cardiol Heart Vasc
Abumayyaleh M, Schupp T, Behnes M, Akin I.   +3 more
europepmc   +1 more source

Aberrant skeletal muscle morphogenesis and myofiber differentiation characterize equine myotonic dystrophy. [PDF]

PLoS One
Valberg SJ, Williams ZJ, Ames EG, Mickelson JR, Nout-Lomas YS, Landolt G, Sanz M, Gardner K.   +7 more
europepmc   +1 more source

Quantitative susceptibility mapping in myotonic dystrophy: clinical relevance of subcortical iron accumulation. [PDF]

Brain Commun
Fiscone C, Rochat MJ, De Pasqua S, Mitolo M, Vornetti G, Bartiromo F, Cirignotta L, Pizza F, Nardozza M, Venturi G, Manners DN, Avoni P, Liguori R, Tonon C, Lodi R.   +14 more
europepmc   +1 more source

Effect of exercise training on clinical and physiological variables in adults with myotonic dystrophy type 1: a systematic review and meta-analysis. [PDF]

J Neurol
Shetty S, Luo Y, Thomas A, Gamil K, Saxena I, Guha S, Vohra R, Lott DJ.   +7 more
europepmc   +1 more source

Identification of enzymatically modified isoquercitrin as a therapeutic lead for myotonic dystrophy type 1. [PDF]

NAR Mol Med
Mishra SK, Hicks SM, Frias JA, Zhang J, Handley MT, Vangaveti S, Reid TS, Pandey A, McMichael O, Crumbaugh C, Provenzano M, Hale MA, Johnson NE, Nakamori M, Cleary JD, Reddy K, Berglund JA.   +16 more
europepmc   +1 more source

Corpus Callosum Diffusion Restriction in Neonatal Congenital Myotonic Dystrophy. [PDF]

Cureus
Sakatani N, Ikeda H, Inami Y, Noguchi Y, Fujii K.   +4 more
europepmc   +1 more source